ATE516356T1 - Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung - Google Patents

Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Info

Publication number
ATE516356T1
ATE516356T1 AT02806841T AT02806841T ATE516356T1 AT E516356 T1 ATE516356 T1 AT E516356T1 AT 02806841 T AT02806841 T AT 02806841T AT 02806841 T AT02806841 T AT 02806841T AT E516356 T1 ATE516356 T1 AT E516356T1
Authority
AT
Austria
Prior art keywords
lysostaphin
staphylolytic
supported
improved
effect
Prior art date
Application number
AT02806841T
Other languages
English (en)
Inventor
Jeffrey Stinson
Lioubov Grinberg
Andrew Lees
James Mond
John Kokai-Kun
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Application granted granted Critical
Publication of ATE516356T1 publication Critical patent/ATE516356T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02806841T 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung ATE516356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34180401P 2001-12-21 2001-12-21
PCT/US2002/040924 WO2003082184A2 (en) 2001-12-21 2002-12-23 Truncated lysostaphin molecule with enhanced staphylolytic activity

Publications (1)

Publication Number Publication Date
ATE516356T1 true ATE516356T1 (de) 2011-07-15

Family

ID=28675229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806841T ATE516356T1 (de) 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Country Status (7)

Country Link
US (1) US20050118159A1 (de)
EP (1) EP1465990B1 (de)
JP (1) JP4348194B2 (de)
AT (1) ATE516356T1 (de)
AU (1) AU2002367820B2 (de)
CA (1) CA2469720A1 (de)
WO (1) WO2003082184A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
CN100475965C (zh) * 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2015020765A2 (en) * 2013-08-06 2015-02-12 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
CN106148254B (zh) * 2015-03-26 2019-11-12 南京华贞生物医药科技有限公司 一种用于减肥降脂的转化体及其构建方法与应用
CN107916244A (zh) * 2017-06-20 2018-04-17 江西嘉博生物工程有限公司 一种表达溶葡球菌素基因的重组乳酸乳球菌的构建方法及应用
AU2018379996A1 (en) * 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
CN115976158B (zh) * 2023-03-16 2023-07-04 百葵锐(天津)生物科技有限公司 一种裂解酶酶活性测定方法
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
EP4719330A1 (de) 2023-06-02 2026-04-08 L'oreal Kosmetische zusammensetzung mit einem endolysin aus einem staphylococcus-aureus-phagen und einem aromatischen alkohol
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149205B1 (fr) 2023-06-02 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3152394B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
FR3152393B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5011772A (en) * 1988-02-05 1991-04-30 Public Health Research Institute Of The City Of N.Y. High yield protein production system
DE4425645A1 (de) * 1994-07-20 1996-02-22 Mueller Karl & Co Kg Deletiertes Lysostaphingen von Staphylococcus simulans
CA2211293A1 (en) * 1997-07-23 1999-01-23 Immunova Ltee Recombinant lysostaphin analogs
US6028051A (en) * 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
AU4706799A (en) * 1998-06-22 2000-01-10 University Of Vermont And State Agricultural College, The Treatment of (staphylococcus) infections
ATE430799T1 (de) * 1999-10-19 2009-05-15 Bharat Biotech International L Expression von rekombinantem, reifem lysostaphin
AU2001256350A1 (en) * 2000-05-12 2001-11-20 Bayer Aktiengesellschaft Regulation of human lysostaphin-like protease

Also Published As

Publication number Publication date
CA2469720A1 (en) 2003-10-09
WO2003082184A3 (en) 2004-07-22
JP4348194B2 (ja) 2009-10-21
AU2002367820A1 (en) 2003-10-13
EP1465990B1 (de) 2011-07-13
US20050118159A1 (en) 2005-06-02
JP2005519628A (ja) 2005-07-07
EP1465990A4 (de) 2006-06-28
WO2003082184A2 (en) 2003-10-09
AU2002367820B2 (en) 2007-11-01
EP1465990A2 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
ATE516356T1 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
DE60127933D1 (de) Chimäre proteine und anwendungen
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
ATE552854T1 (de) Gezielte biozide
NO20024157L (no) Kasein-avledete peptider og anvendelser derav i terapi
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
EA201001212A8 (ru) Лечение микробных инфекций
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
NO20082628L (no) Stabile proteinformuleringer
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
EE200200625A (et) Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DK1278868T3 (da) Muteret form af arginindeiminase
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties